Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of HTL0018318 in healthy younger and elderly adults
NL-OMON42509Phase 1Active, not recruiting
- Sponsor
- Heptares Therapeutics
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) and schizophrenia comparing HTL0018318 with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events, Concomitant medication use and 12 more. Started Oct 2015; status: active, not recruiting.
02
Drugs
HTL0018318
03
Conditions
Alzheimer's disease (AD)schizophrenia
Beyond the preview
Go deeper on NL-OMON42509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42509.